Article

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition

2018-05-17

Abstract excerpt

<h4>Abstract:</h4> Hypertrophic cardiomyopathies (HCM) result from distinct single-point mutations in sarcomeric proteins that lead to muscle hypercontractility. While different models account for a pathological increase in the power output, clear understanding of the molecular basis of dysfunction in HCM is the mandatory next step to improve current treatments. An optimized quasi-atomic model of the sequestered...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 843712fb-b352-58b3-9dde-110e0410f8aa
DOI: 10.1101/324830

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionDOI 10.1101/324830Read

Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibitionSemantic proximity Read

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read

Hypertrophic cardiomyopathy ß-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super-relaxed stateSemantic proximity Read

Beyond the myosin mesa: a potential unifying hypothesis on the underlying molecular basis of hyper-contractility caused by a majority of hypertrophic cardiomyopathy mutationsSemantic proximity Read

Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases.Semantic proximity Read

Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin functionSemantic proximity Read

Biophysical properties of human β-cardiac myosin with converter mutations that cause hypertrophic cardiomyopathySemantic proximity Read

The hypertrophic cardiomyopathy mutation G768R makes cardiac myosin a high duty ratio motorSemantic proximity Read

Mavacamten stabilizes a folded-back sequestered super-relaxed state of β-cardiac myosinSemantic proximity Read

Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocitySemantic proximity Read

Tail Length and E525K Dilated Cardiomyopathy Mutant Alter Human β-Cardiac Myosin Super-Relaxed StateSemantic proximity Read

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy.Semantic proximity Read